CD274 and breast carcinoma: Furthermore, recent trials have shown that a subgroup of breast carcinomas has an enhanced response to immune checkpoint inhibitors, which target programmed death 1 (PD‐1) or programmed death ligand 1 (PD‐L1), combined with NAT or conventional chemotherapy.19, 20, 21